PENERAPAN AMANAT AGUNG DALAM KONTEKS KEMAJEMUKAN INDONESIA: SUATU PENDEKATAN INKLUSIF-TRANSFORMATIF
Manna Rafflesia · 29.04.2026 · 12 (2) · 405-419
DOI: 10.38091/man_raf.v12i2.549 ↗Kurz gefasst
Fachartikel in der Zeitschrift Manna Rafflesia, online erschienen am 29.04.2026. Verfasst von Hikman Sirait und 1 weiteren Autor:innen. Die Arbeit nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Abstract (Originalsprache)
Indonesia is a country with a highly diverse population. However, intolerance and radicalism frequently lead to horizontal conflicts. The aim of this research is to apply the Great Commission as a relevant framework for developing the Gospel message so that it may be accepted by Indonesia’s vast and diverse population. Employing a qualitative method with a literature review and descriptive data analysis approach, it can be concluded that Indonesia’s diversity does not render the Gospel unacceptable or a failure; but rather that the Gospel can be accepted in their own respective ways; thus, the integration of the Gospel and contextualisation must be harmonised so that the Gospel message aligns with cultural and ethnic contexts, whilst deep social ministry will facilitate serving as a bridge for those wishing to proclaim the Gospel to Indonesia’s diverse society.
Zitieren
APA
Sirait, H., & Lim, S. (2026). PENERAPAN AMANAT AGUNG DALAM KONTEKS KEMAJEMUKAN INDONESIA: SUATU PENDEKATAN INKLUSIF-TRANSFORMATIF. Manna Rafflesia, 12(2), 405-419. https://doi.org/10.38091/man_raf.v12i2.549
Vancouver
Sirait H, Lim S. PENERAPAN AMANAT AGUNG DALAM KONTEKS KEMAJEMUKAN INDONESIA: SUATU PENDEKATAN INKLUSIF-TRANSFORMATIF. Manna Rafflesia. 2026;12(2):405-419. doi:10.38091/man_raf.v12i2.549
BibTeX
@article{Sirait2026,
author = {Sirait, Hikman and Lim, Suleman},
title = {PENERAPAN AMANAT AGUNG DALAM KONTEKS KEMAJEMUKAN INDONESIA: SUATU PENDEKATAN INKLUSIF-TRANSFORMATIF},
journal = {Manna Rafflesia},
year = {2026},
volume = {12},
number = {2},
pages = {405--419},
doi = {10.38091/man_raf.v12i2.549}
}
EUVIMED